Transaction Details

Footnotes

The performance stock option grant was approved by the Board of Directors of Ocular Therapeutix, Inc. (the "Corporation") on February 11, 2025 (the "Grant Date"), the commencement of vesting of which was contingent upon shareholder approval of an amendment to the Corporation's 2021 Stock Incentive Plan, as amended. Shareholder approval of such amendment was received on June 11, 2025. | Pursuant to a performance stock option agreement (the "Option Agreement"), the shares underlying the performance stock option can be earned during the five-year period beginning on the Grant Date in four equal tranches based on the achievement of share price hurdles if the Corporation's consecutive 60-day closing share price average meets or exceeds $15.00, $20.00, $25.00, and $30.00 per share (each, a "Share Price Hurdle"). Shares underlying the performance stock option that are earned shall vest on the later of (i) the achievement of the applicable Share Price Hurdle or (ii) the three-year anniversary of the Grant Date, in each case subject to the reporting person's continued service to the Corporation. The performance stock option is subject to earlier vesting upon certain qualifying termination events pursuant to the Option Agreement.